Search research articles
Contact Us
Filters
Showing results (31-40 of 62) with videos related to
Page
of 7
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
Owen O'Connor, John Wright, Craig H Moskowitz, et al.
Leukemia & Lymphoma
|
January 16, 2023
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <i>CREBBP</i> or <i>EP300</i> mutations: an open label phase II study
David Qualls, Ariela Noy, David Straus, et al.
British Journal of Haematology
|
June 8, 2004
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
Carol S Portlock, Gerard B Donnelly, Jing Qin, et al.
Leukemia & Lymphoma
|
August 27, 2020
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population
Paola Ghione, Shunan Qi, Brandon S Imber, et al.
Blood
|
January 24, 2004
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani, Andrew D Zelenetz, Stephen D Nimer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 1, 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
Heiko Schöder, Andrew D Zelenetz, Paul Hamlin, et al.
Journal of Community Genetics
|
July 18, 2020
Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial
Nassim Anderson, Arash Delavar, Danielle Novetsky Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Owen A O'Connor, John Wright, Craig Moskowitz, et al.
British Journal of Haematology
|
July 24, 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano, Carol Portlock, Craig Moskowitz, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 62) with videos related to
Sort By:
Page
of 7
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
Owen O'Connor, John Wright, Craig H Moskowitz, et al.
Leukemia & Lymphoma
|
January 16, 2023
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <i>CREBBP</i> or <i>EP300</i> mutations: an open label phase II study
David Qualls, Ariela Noy, David Straus, et al.
British Journal of Haematology
|
June 8, 2004
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
Carol S Portlock, Gerard B Donnelly, Jing Qin, et al.
Leukemia & Lymphoma
|
August 27, 2020
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population
Paola Ghione, Shunan Qi, Brandon S Imber, et al.
Blood
|
January 24, 2004
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani, Andrew D Zelenetz, Stephen D Nimer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 1, 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
Heiko Schöder, Andrew D Zelenetz, Paul Hamlin, et al.
Journal of Community Genetics
|
July 18, 2020
Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial
Nassim Anderson, Arash Delavar, Danielle Novetsky Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Owen A O'Connor, John Wright, Craig Moskowitz, et al.
British Journal of Haematology
|
July 24, 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano, Carol Portlock, Craig Moskowitz, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Page
of 7